NPS Pharmaceuticals Inc., of Bedminster, N.J., reported findings from the Phase III REPLACE study of Natpara (recombinant human parathyroid hormone), showing that Natpara initiated bone remodeling as demonstrated by significant increases in bone turnover markers.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter